Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

12.1%

7 terminated/withdrawn out of 58 trials

Success Rate

56.3%

-30.3% vs industry average

Late-Stage Pipeline

12%

7 trials in Phase 3/4

Results Transparency

0%

0 of 9 completed trials have results

Key Signals

26 recruiting

Enrollment Performance

Analytics

Phase 1
41(71.9%)
Phase 2
8(14.0%)
Phase 3
7(12.3%)
Early Phase 1
1(1.8%)
57Total
Phase 1(41)
Phase 2(8)
Phase 3(7)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (58)

Showing 20 of 58 trials
NCT07428486Phase 1Withdrawn

A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

Role: collaborator

NCT07178912Phase 2Not Yet Recruiting

Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

Role: collaborator

NCT03913949Phase 1Active Not Recruiting

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Role: lead

NCT06051409Phase 3Recruiting

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

Role: lead

NCT04501120Phase 1Recruiting

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Role: lead

NCT06401603Phase 1Recruiting

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

Role: collaborator

NCT06817720Phase 2Recruiting

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Role: collaborator

NCT05773586Phase 1Recruiting

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918.

Role: lead

NCT03594422Phase 1Recruiting

A Study of HQP1351 in Patients With GIST or Other Solid Tumors

Role: lead

NCT05147467Phase 2Recruiting

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Role: lead

NCT03781986Phase 1Active Not Recruiting

APG-115 in Salivary Gland Cancer Trial

Role: collaborator

NCT07424833Phase 1Not Yet Recruiting

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

Role: lead

NCT04284488Phase 1Terminated

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Role: lead

NCT04643405Phase 1Terminated

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

Role: lead

NCT07282093Phase 1Recruiting

Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment

Role: lead

NCT06182969Phase 1Recruiting

A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

Role: lead

NCT06389292Phase 3Recruiting

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

Role: lead

NCT06641414Phase 3Recruiting

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

Role: lead

NCT04260022Phase 1Recruiting

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Role: lead

NCT04496349Phase 2Recruiting

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

Role: lead